ALHC vs. NBIX: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALHC and NBIX, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
NBIX stands out with 11.93 billion USD in market value—about 3.93× ALHC’s market cap of 3.03 billion USD.
ALHC’s beta of 1.33 points to much larger expected swings compared to NBIX’s calmer 0.26, suggesting both higher upside and downside potential.
| Symbol | ALHC | NBIX |
|---|---|---|
| Company Name | Alignment Healthcare, Inc. | Neurocrine Biosciences, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Healthcare Plans | Drug Manufacturers - Specialty & Generic |
| CEO | Mr. John E. Kao | Mr. Kyle W. Gano Ph.D. |
| Price | 15.33 USD | 120.56 USD |
| Market Cap | 3.03 billion USD | 11.93 billion USD |
| Beta | 1.33 | 0.26 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | March 26, 2021 | May 23, 1996 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALHC and NBIX over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALHC and NBIX based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALHC posts a negative P/E of -32.75, reflecting last year’s net loss, while NBIX at 39.31 signals healthy earnings.
- ALHC posts a negative forward PEG of -1.11, hinting at anticipated earnings decline, whereas NBIX at 1.35 has projections for stable or growing earnings.
| Symbol | ALHC | NBIX |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -32.75 | 39.31 |
| Forward PEG Ratio (TTM) | -1.11 | 1.35 |
| Price-to-Sales Ratio (P/S, TTM) | 1.01 | 4.95 |
| Price-to-Book Ratio (P/B, TTM) | 27.45 | 4.74 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 159.00 | 24.24 |
| EV-to-EBITDA (TTM) | -64.47 | 22.57 |
| EV-to-Sales (TTM) | 0.86 | 5.05 |
| EV-to-Free Cash Flow (TTM) | 136.01 | 24.76 |
Dividend Comparison
Neither ALHC nor NBIX currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALHC | NBIX |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALHC and NBIX, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ALHC has negative EBIT (interest coverage -2.98), unable to cover interest, while NBIX shows “--” (negligible interest expense).
| Symbol | ALHC | NBIX |
|---|---|---|
| Current Ratio (TTM) | 1.69 | 3.13 |
| Quick Ratio (TTM) | 1.69 | 3.02 |
| Debt-to-Equity Ratio (TTM) | 0.07 | 0.18 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.12 |
| Interest Coverage Ratio (TTM) | -2.98 | -- |